



EUROPEAN MEDICINES AGENCY
SCIENCE MEDICINES HEALTH

EMA/466271/2013

European Medicines Agency decision

P/0208/2013

of 3 September 2013

on the acceptance of a modification of an agreed paediatric investigation plan for chimeric anti-disialoganglioside (GD2) monoclonal antibody (NSC764038) (EMA-001285-PIP01-12-M01) in accordance with Regulation (EC) No 1901/2006 of the European Parliament and of the Council

Disclaimer

This Decision does not constitute entitlement to the rewards and incentives referred to in Title V of Regulation (EC) No 1901/2006.

Only the English text is authentic.



European Medicines Agency decision

P/0208/2013

of 3 September 2013

on the acceptance of a modification of an agreed paediatric investigation plan for chimeric anti-disialoganglioside (GD2) monoclonal antibody (NSC764038) (EMEA-001285-PIP01-12-M01) in accordance with Regulation (EC) No 1901/2006 of the European Parliament and of the Council

The European Medicines Agency,

Having regard to the Treaty on the Functioning of the European Union,

Having regard to Regulation (EC) No 1901/2006 of the European Parliament and of the Council of 12 December 2006 on medicinal products for paediatric use and amending Regulation (EEC) No. 1768/92, Directive 2001/20/EC, Directive 2001/83/EC and Regulation (EC) No 726/2004¹,

Having regard to Regulation (EC) No 726/2004 of the European Parliament and of the Council of 31 March 2004 laying down Community procedures for the authorisation and supervision of medicinal products for human and veterinary use and establishing a European Medicines Agency²,

Having regard to the European Medicines Agency's decision P/0295/2012 issued on 18 December 2012,

Having regard to the application submitted by United Therapeutics Europe Limited on 24 April 2013 under Article 22 of Regulation (EC) No 1901/2006 proposing changes to the agreed paediatric investigation plan with a deferral and a waiver,

Having regard to the opinion of the Paediatric Committee of the European Medicines Agency, issued on 19 July 2013, in accordance with Article 22 of Regulation (EC) No 1901/2006,

Having regard to Article 25 of Regulation (EC) No 1901/2006,

Whereas:

- (1) The Paediatric Committee of the European Medicines Agency has given an opinion on the acceptance of changes to the agreed paediatric investigation plan and to the deferral.
- (2) It is therefore appropriate to adopt a decision on the acceptance of changes to the agreed paediatric investigation plan, including changes to the deferral.

¹ OJ L 378, 27.12.2006, p.1.

² OJ L 136, 30.4.2004, p. 1.

Has adopted this decision:

Article 1

Changes to the agreed paediatric investigation plan for chimeric anti-disialoganglioside (GD2) monoclonal antibody (NSC764038), solution for infusion, intravenous use, including changes to the deferral, are hereby accepted in the scope set out in the opinion of the Paediatric Committee of the European Medicines Agency annexed hereto, together with its appendices.

Article 2

This decision is addressed to United Therapeutics Europe Limited, Unither House, Curfew Bell Road, Chertsey, KT16 9FG – Surrey, United Kingdom.

Done at London, 3 September 2013

For the European Medicines Agency
Guido Rasi
Executive Director
(Signature on file)

EMA/PDCO/272234/2013 Corr

Opinion of the Paediatric Committee on the acceptance of a modification of an agreed Paediatric Investigation Plan

EMA-001285-PIP01-12-M01

Scope of the application

Active substance(s):

Chimeric anti-disialoganglioside (GD2) monoclonal antibody (NSC764038)

Condition(s):

Treatment of neuroblastoma

Pharmaceutical form(s):

Solution for infusion

Route(s) of administration:

Intravenous use

Name / corporate name of the PIP applicant:

United Therapeutics Europe Limited

Basis for opinion

Pursuant to Article 22 of Regulation (EC) No 1901/2006 as amended, United Therapeutics Europe Limited submitted to the European Medicines Agency on 24 April 2013 an application for modification of the agreed paediatric investigation plan with a deferral and a waiver as set out in the European Medicines Agency's decision P/0295/2012 issued on 18 December 2012.

The application for modification proposed changes to the agreed paediatric investigation plan and to the deferral.

The procedure started on 22 May 2013.

Scope of the modification

Some measures and timelines of the Paediatric Investigation Plan have been modified.

Opinion

1. The Paediatric Committee, having assessed the application in accordance with Article 22 of Regulation (EC) No 1901/2006 as amended, recommends as set out in the appended summary report:
 - to agree to changes to the paediatric investigation plan and to the deferral in the scope set out in the Annex I of this opinion.

The Norwegian Paediatric Committee member agrees with the above-mentioned recommendation of the Paediatric Committee.

2. The measures and timelines of the paediatric investigation plan and the subset(s) of the paediatric population and condition(s) covered by the waiver are set out in the Annex I.

This opinion is forwarded to the applicant and the Executive Director of the European Medicines Agency, together with its annex and appendix.

London, 19 July 2013

On behalf of the Paediatric Committee
Dr Daniel Brasseur, Chairman
(Signature on file)

Annex I

The subset(s) of the paediatric population and condition(s) covered by the waiver and the measures and timelines of the agreed Paediatric Investigation Plan

1. Waiver

1.1. Condition: treatment of neuroblastoma

The waiver applies to:

- the paediatric population from birth to less than 28 days;
- for solution for infusion, intravenous use;
- on the grounds that clinical studies with the specific medicinal product cannot be expected to be of significant therapeutic benefit to or fulfil a therapeutic need of the specified paediatric population.

2. Paediatric Investigation Plan

2.1. Condition: treatment of neuroblastoma

2.1.1. Indication(s) targeted by the PIP

Treatment of paediatric patients with high-risk neuroblastoma as part of a consolidation therapy in combination with GM-CSF, interleukin-2 and retinoic acid after achieving at least a partial response and after high-dose chemotherapy with autologous haematopoietic stem cell transplantation.

2.1.2. Subset(s) of the paediatric population concerned by the paediatric development

From 28 days to less than 18 years of age.

2.1.3. Pharmaceutical form(s)

Solution for infusion.

2.1.4. Studies

Area	Number of studies	Description
Quality	0	Not applicable.
Non-clinical	0	Not applicable.
Clinical	7	Study 1: Open-label, single-arm study to evaluate toxicity and activity of chimeric anti-disialoganglioside (GD2) monoclonal antibody NSC623408 in combination with GM-CSF in patients from 2 years to less than 18 years of age (and adults) with recurrent neuroblastoma Study 2: Open-label, dose-escalating study to evaluate tolerability of NSC623408 in combination with GM-CSF in patients from 28 days to less than 18 years of

Area	Number of studies	Description
		age with neuroblastoma Study 3: Open-label, dose escalating study to evaluate tolerability of NSC623408 in combination with GM-CSF and interleukin-2 in patients from 28 days to less than 18 years of age with neuroblastoma Study 4: Open-label, randomized, active-controlled study to evaluate efficacy and toxicity of NSC623408 in combination with GM-CSF, interleukin-2 and isotretinoin versus isotretinoin alone in patients from 28 days to less than 18 years of age with high-risk neuroblastoma. Study 5: Open-label, single-arm study to evaluate safety and activity of NSC623408 in combination with GM-CSF, interleukin-2 and isotretinoin in patients from 28 days to less than 18 years of age with high-risk neuroblastoma. Study 6: Open-label, single-arm study to evaluate safety of NSC623408 in combination with GM-CSF, interleukin-2 and isotretinoin in patients from 28 days to less than 18 years of age with high-risk neuroblastoma. Study 7: Open-label, randomized cross-over study to evaluate pharmacokinetics, tolerability and safety of NSC764038 compared to NSC623408 in patients from 28 days to less than 10 years of age with high-risk neuroblastoma.

3. Follow-up, completion and deferral of PIP

Concerns on potential long term safety and efficacy issues in relation to paediatric use:	Yes.
Date of completion of the paediatric investigation plan:	By January 2014.
Deferral for one or more studies contained in the paediatric investigation plan:	Yes.